About Aldeyra

Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing, and commercializing products that treat inflammation and inborn errors of metabolism.  Aldeyra's lead product candidate, reproxalap (formerly known as ADX-102), is a small molecule aldehyde sequestering agent in Phase 2b clinical development for the treatment of dry eye disease, and Phase 3 clinical development for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome.

Press Releases

Mar 29, 2018
Mar 22, 2018
Feb 27, 2018
Feb 21, 2018
Jan 30, 2018

Corporate Presentation


Scientific Posters & Presentations